about
The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersThe Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans.Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical ImportanceClinical Pharmacokinetics in Kidney Disease: Fundamental PrinciplesBetter outcomes for patients with goutPredictors of Success in Gout TreatmentClinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing RegimensSodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney diseaseEducation to improve vancomycin use - The perspectives of educators and education recipientsDetermination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detectionIs the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysisImproving adherence to urate-lowering therapy in people living with goutA pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjectsBarriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncologyComparison of the Area-Under-The-Curve for Vancomycin Estimated Using Compartmental and Non-compartmental Methods in Adult Patients with Normal Renal Function
P50
Q36689589-992708CE-6E0A-43C1-A174-7A31BBC91576Q36924379-E9572F20-41E6-47CA-93FD-C2EAC634D362Q36999783-5468ADF2-3202-4C7B-BDBB-AFF7573D1BDEQ57112262-C0D28B08-4AAF-4111-AED8-38888AC8B4F8Q89207253-BF70BEF8-127E-49CA-BCEE-99F7A228781AQ89871224-CFE7E238-4D99-404E-9676-970DD27B658FQ89960311-C01437AB-FB3A-4A10-8CC5-7D1DE1559315Q90451490-56B0C9D3-64C0-463E-BCCF-440512F6EBADQ92391048-07A7AF95-89CB-4F13-B5D8-EF34438DBB1DQ92847323-4DAE1D9B-7503-4F5B-8BA8-A3D24B887091Q92904049-5AAB1BB4-5044-4B0C-BE6F-3C8F505F9AC9Q93026902-51B2E8F6-FC9A-4F11-9281-7894DD2D53E8Q93097323-435DF382-3668-47E8-A447-FD62648D4CCCQ94583920-0905FA55-28FF-4A6F-B784-4D4FCA2E0AEEQ95281808-5A0C0399-F9B7-4530-A158-22CD9E409A93Q95764950-C876BDBC-E420-47D8-AF06-9717134C4C36
P50
description
researcher
@en
wetenschapper
@nl
name
Sophie L Stocker
@en
Sophie L Stocker
@nl
type
label
Sophie L Stocker
@en
Sophie L Stocker
@nl
prefLabel
Sophie L Stocker
@en
Sophie L Stocker
@nl
P31
P496
0000-0002-2114-587X